ClinicalTrials.gg
CompletedNCT02747342Updated Jul 21, 2020

A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer

A Phase 1 interventional study of SHR3680; SHR3162 in Neoplasm and Prostate Cancer, sponsored by Atridia Pty Ltd.. Completed at 6 sites in Australia. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-21.

Primary conditionProstatic NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Prostatic Neoplasms
Why
  1. The study's listed conditions name Prostatic Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Atridia Pty Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing rezvilutamide in Prostatic Neoplasms — 10 open to participants now, 11 under way, 3 of them phase 3. rezvilutamide · Prostatic Neoplasms.

Enrollment
13th of 18
33 · median 98
Started
2016
with 1 other
Phase 1
4 of 18
1 open now
Registered
2nd of 18
by date
Lead sponsor
1 of 18
Atridia Pty Ltd.

Among the 18 studies testing rezvilutamide in Prostatic Neoplasms, this one is the 13th largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 1, and was the 2nd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

10 of the 18 studies testing rezvilutamide in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

About rezvilutamide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing rezvilutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a multicenter, dose-escalation/expansion phase 1 trial to evaluate the safety, tolerability and efficacy of SHR3680 with or without SHR3162 given orally to subjects with metastatic castration-resistant prostate cancer (mCRPC).

Read the detailed description

This study consists of 2 Part. In the Part 1 (dose escalation phase), up to 4 dose levels of SHR3680 will be investigated with a sequential "3+3" design (3 or 6 participants in each dose level). There will be a single-dose pharmacokinetic (PK) run-in period (7 days). Following the first dose, participants will enter a 1 week treatment-free period to evaluate safety and single-dose PK. If not dose-limiting toxicities (DLTs) are observed during the 1-week period, SHR3680 administration will resume at the same dose level.

In the Part 2a (expansion phase), up to 9 additional participants will be enrolled at the MTD or recommended phase 2 dose (RP2D). The purpose of the expansion part of the study is to explore the clinical benefits of SHR3680 and to further identify its PK features.

In Part 2b (combination phase), two dose cohorts of SHR3162 combine with SHR3680 at fixed dose will be investigated.

03

Conditions studied

  • Neoplasm
  • Prostate Cancer

Browse trials for

Keywords

  • Metastatic castration-resistant prostate cancer
04

In context

Prostatic Neoplasms Reclassified

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

This study's enrollment of 33 is below the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Atridia Pty Ltd. is the lead sponsor of 36 studies on the registry; 2 are open to participants now.

Compared within Prostatic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male 18 years and older
  2. Ability to understand the purposes and risks of the trial and his/her signed form approved by the HREC of the trial site, which must be obtained before entering the trial
  3. or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
  4. For patients who have not had an orchiectomy, there must be a plan to maintain effective GnRH-analogue therapy for the duration of the trial
  5. Serum testosterone level \< 1.7 nmol/L (50 ng/dL) at the screening visit
  6. Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or orchiectomy (i.e., surgical or medical castration)
  7. Progressive disease by PSA or imaging after docetaxel-based chemotherapy or abiraterone in the setting of medical or surgical castration. Prior enzalutamide is allowed as long as patients had a PSA response >50% or were treated for at least 6 months. Disease progression for study entry is defined by one or more of the following three criteria:

    • PSA progression defined by a minimum of three rising PSA levels with an interval of ≥ 1 week between each determination. The PSA value at the Screening visit should be ≥2 μg/L (2 ng/mL)
    • Soft tissue disease progression defined by (Appendix A)
    • Bone disease progression defined by two or more new lesions on the bone scan
  8. performance status of 0 or 1
  9. of at least 6 months
  10. Able to swallow the study drug and comply with study requirements
  11. Acceptable liver function defined as:

    • Total ≤ 1.5 times the (ULN)
    • (AST) and alanine aminotransferase (ALT) ≤ 3 times ULN; however, ≤ 5 times ULN in a subject who has liver or has been treated with biliary drainage
  12. Acceptable renal function defined below:

    • Serum creatinine ≤ 1.5 times ULN
  13. Acceptable hematologic status (without hematologic support including hematopoietic factor, blood transfusion) defined below:

    • (ANC) ≥ 1,500/μL
    • count ≥ 100,000/μL
    • ≥ 9.0 g/dL

Exclusion criteria

Exclusion Criteria

  1. Treatment with AR antagonists (enzalutamide, bicalutamide, flutamide, nilutamide), 5-α reductase inhibitors (finasteride, dutasteride), estrogens, or chemotherapy within 4 weeks of enrollment (day 1 visit) or plans to initiate treatment with any of these drugs during the study. Ongoing therapy with bisphosphonates or Rank Ligand inhibitors are acceptable.
  2. Prior treatment with a PARP inhibitor or have plans to initiate treatment with a PARP inhibitor during the study (only apply to subjects participating in Part 2b)
  3. Treatment with therapeutic immunizations for prostate cancer (e.g., PROVENGE®) or plans to initiate treatment with any of these therapies during the study
  4. in the brain or active epidural disease (Note: patients with treated for epidural disease are allowed to enter the trial)
  5. Use of herbal products that may decrease PSA levels (e.g., saw palmetto) or systemic greater than the equivalent of 10 mg of prednisone/prednisolone per day within 4 weeks of enrollment (day 1 visit) or plans to initiate treatment with any of these therapies during the study
  6. History of another within the previous 5 years other than curatively treated non-melanomatous skin cancer
  7. Radiation therapy within 3 weeks (if single fraction of radiotherapy, then a 1-week gap is allowable) and radionuclide therapy within 8 weeks of enrollment (Day 1 visit). Any radiotherapy-related AE > Grade 1 before the start of study treatment.
  8. Have used or plan to use from 30 days prior to enrollment (day 1 visit) through to the end of the study medications known to lower the seizure threshold or prolong the -interval (described in Appendix I)
  9. Cardiac disease with (NYHA) Class III or IV, including congestive heart failure, myocardial infarction within 6 months prior to the trial entry, unstable arrhythmia, or symptomatic peripheral arterial vascular disease
  10. Severe concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment
  11. History of seizure, including any febrile seizure, loss of consciousness, or within 12 months of enrollment (day 1 visit), or any condition that may pre-dispose to seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss of consciousness requiring hospitalization)
  12. Use of an agent within 4 weeks of enrollment or plans to initiate treatment with an investigational agent during the study
  13. Major surgery, other than diagnostic surgery, within 4 weeks prior to trial entry, without complete recovery
  14. Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within the last 3 months)
  15. Structurally unstable bone lesions suggesting impending fracture
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    SHR3680; SHR3680+SHR3162

    In dose esclation and expansion phase, SHR3680 will be administered orally In combination phase, SHR3680 will be administered together with SHR3162

    Drug: SHR3680; SHR3162

Interventions

  • DrugSHR3680; SHR3162

    Drug pages: Rezvilutamide · Fluzoparib

    SHR3680 will be administered orally in dose escalation/expansion phase, SHR3680 will be administered orally at a fixed dose together with SHR3162 in combination phase.

07

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    MTD is defined as the maximum dose level at which no more than 1 out of 3 participants experience a DLT within the first 4 weeks of multiple dosing

    Time frame: 4 weeks

  2. Recommended Phase 2 doses (RP2Ds)

    RP2D will be determined based on the available data for toxicity and PK.

    Time frame: 24 months

Secondary outcomes

  1. Number of participants with treatment-emergent adverse events

    The number and proportion of subjects experiencing treatment-emergent AEs (TEAE); drug exposure; clinically significant changes in laboratory parameters, vital signs, physical examinations, weight, ECOG performance status, ECG abnormalities, number and causes of deaths.

    Time frame: 24 months

  2. The AUC of SHR3680 and SHR3162 (area under the curve)

    The AUC of SHR3680 given as BID 240 mg tablets in combination with SHR3162

    Time frame: 4 weeks

  3. The cMax (peak plasma concentration) of SHR3680 and SHR3162

    The cMax (peak plasma concentration) of SHR3680 given as BID 240 mg tablets in combination with SHR3162

    Time frame: 4 weeks

  4. PSA reduction

    Percentage of participants reaching at least a 50% reduction in prostate specific antigen (PSA) at Week 12 as compared to baseline

    Time frame: 12 weeks

  5. PSA progression

    Time to reach the PSA Progression

    Time frame: 24 months

  6. Objective response rate (ORR)

    the proportion of patients with tumor size reduction of a predefined amount and for a minimum time periodthe proportion of patients with tumor size reduction of a predefined amount and for a minimum time periodthe proportion of patients with tumor size reduction of a predefined amount and for a minimum time periodthe proportion of patients with tumor size reduction of a predefined amount and for a minimum time periodthe proportion of patients with tumor size reduction of a predefined amount and for a minimum time periodthe proportion of patients with tumor size reduction of a predefined amount and for a minimum time periodthe proportion of patients with tumor size reduction of a predefined amount and for a minimum time periodthe proportion of patients with tumor size reduction of a predefined amount and for a minimum time period

    Time frame: 24 months

  7. Radiological progression-free survival (PFS)

    the length of time during and after the treatment

    Time frame: 24 months

Other outcomes

  1. Homologous recombination deficiency (HRD)

    Homologous recombination deficiency (HRD) as a predictive biomarker of response in patients with Metastatic castration resistant prostate cancer

    Time frame: 2 weeks

08

Study locations

6 sites
  • Border Medical Oncology
    Albury, New South Wales 2640, Australia
  • Chris O'Brien Lifehouse
    Camperdown, New South Wales 2050, Australia
  • St George Hospital
    Kogarah, New South Wales 2217, Australia
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • Westmead Hospital
    Sydney, New South Wales 2145, Australia
  • Icon Cancer Centre
    South Brisbane, Queensland 4101, Australia
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Jun 2019, 33 months.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 33 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2016
First posted
Apr 21, 2016
StartActual
Sep 2016
Primary completionActual
Jun 28, 2019
CompletionActual
Jun 28, 2020
Last update
Jul 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02747342
Lead sponsor
Atridia Pty Ltd.
Responsible party
Sponsor
First posted
Apr 21, 2016
Start date
Sep 2016
Primary completion
Jun 28, 2019
Completion
Jun 28, 2020
Last update
Jul 21, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rezvilutamide · Fluzoparib

Start the discussion